Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 822
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +18.1%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (418)

clinicaltrialsPublishedShowing 251–300 of 310 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02934204	Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma	unknown	Phase 2	51	Guangdong Provincial People's HospitalOTHER	1	Oct 14, 2016	clinicaltrials
NCT02928575	Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma	unknown	Phase 2	45	Bassam AbdulkarimOTHER	1	Oct 10, 2016	clinicaltrials